About Biomea Fusion, Inc.
https://biomeafusion.comBiomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
CEO
Michael J. M. Hitchcock
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Citigroup
Buy
D. Boral Capital
Buy
HC Wainwright & Co.
Buy
Scotiabank
Sector Outperform
Barclays
Equal Weight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:7.62M
Value:$12.34M
CORMORANT ASSET MANAGEMENT, LP
Shares:3.57M
Value:$5.78M
BLACKROCK INC.
Shares:2.34M
Value:$3.8M
Summary
Showing Top 3 of 82
About Biomea Fusion, Inc.
https://biomeafusion.comBiomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $20.8M ▲ | $-16.41M ▲ | 0% | $-0.27 ▲ | $-15.98M ▲ |
| Q2-2025 | $0 | $20.78M ▼ | $-20.74M ▲ | 0% | $-0.51 ▲ | $-20.24M ▲ |
| Q1-2025 | $0 | $29.71M ▼ | $-29.26M ▲ | 0% | $-0.8 ▲ | $-29.24M ▲ |
| Q4-2024 | $0 | $30.07M ▼ | $-29.3M ▲ | 0% | $-0.81 ▲ | $-29.61M ▲ |
| Q3-2024 | $0 | $34.04M | $-32.79M | 0% | $-0.91 | $-33.6M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $46.64M ▼ | $55.19M ▼ | $39.57M ▼ | $15.62M ▼ |
| Q2-2025 | $56.22M ▲ | $73.16M ▲ | $45.65M ▲ | $27.51M ▼ |
| Q1-2025 | $35.86M ▼ | $55.05M ▼ | $26.32M ▼ | $28.74M ▼ |
| Q4-2024 | $58.28M ▼ | $79.94M ▼ | $28.36M ▼ | $51.57M ▼ |
| Q3-2024 | $87.95M | $110.42M | $34.45M | $75.97M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.41M ▲ | $-12.18M ▲ | $0 | $2.6M ▼ | $-9.58M ▼ | $-12.18M ▲ |
| Q2-2025 | $-20.74M ▲ | $-19.21M ▲ | $0 | $39.57M ▲ | $20.36M ▲ | $-19.21M ▲ |
| Q1-2025 | $-29.26M ▲ | $-25.67M ▲ | $0 ▲ | $3.25M ▲ | $-22.41M ▲ | $-25.67M ▲ |
| Q4-2024 | $-29.3M ▲ | $-30M ▼ | $-82K ▲ | $413K ▲ | $-29.67M ▼ | $-30.09M ▼ |
| Q3-2024 | $-32.79M | $-25.22M | $-186K | $69K | $-25.33M | $-25.4M |
CEO
Michael J. M. Hitchcock
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Citigroup
Buy
D. Boral Capital
Buy
HC Wainwright & Co.
Buy
Scotiabank
Sector Outperform
Barclays
Equal Weight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:7.62M
Value:$12.34M
CORMORANT ASSET MANAGEMENT, LP
Shares:3.57M
Value:$5.78M
BLACKROCK INC.
Shares:2.34M
Value:$3.8M
Summary
Showing Top 3 of 82